Zymeworks To Acquire Theravance Biopharma For $929 Mln In Cash Deal, TBPH Stock Down In Pre-Market

rttnews.com · 2026-06-29

Monday, Zymeworks Inc. (ZYME) agreed to acquire Theravance Biopharma, Inc. (TBPH) in an all-cash deal valued at approximately $929 million, offering $17.00 per share.

Read the full story at rttnews.com →